Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Incyte (INCY)

Incyte names William Meury CEO; Hervé Hoppenot retires as CEO effective June 26, 2025

Neutral Impact 4 of 5 leadership Written later

Incyte said Hervé Hoppenot retired as President and Chief Executive Officer effective June 26, 2025, and will remain on the Board and serve as a special advisor under a transition agreement. The company also appointed William J. Meury as President and Chief Executive Officer and to the Board, effective the same day, with a $1,250,000 initial base salary and a 100% target bonus.

Key points

  • William J. Meury, age 57, was named President, CEO and director effective June 26, 2025; he was previously CEO of Karuna Therapeutics, which was acquired by Bristol-Myers Squibb.
  • Julian C. Baker, Lead Independent Director, became Chairman of the Board effective June 26, 2025.
  • Meury's offer letter provides a 36,101-share sign-on RSU award, 110,630 stock options, a 108,303-share target performance share award, and a one-time 125,000-share target performance share award.
  • Hoppenot will receive his current annual base salary of $1,395,731 for six months, then 50% of that rate, under a transition agreement with a term ending no later than the first anniversary of June 26, 2025.

The filing

CompanyIncyte (INCY)
Form8-K, current report
Filed with the SECJun 27, 2025, 4:54 PM ET
Accession number0001104659-25-063675

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 27, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.